Institute for Molecular Bioscience, The University of Queensland, Brisbane, QC, Australia.
Institute of Biological Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.
Nat Rev Drug Discov. 2021 Apr;20(4):309-325. doi: 10.1038/s41573-020-00135-8. Epub 2021 Feb 3.
Since the introduction of insulin almost a century ago, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain. In this Perspective, we summarize key trends in peptide drug discovery and development, covering the early efforts focused on human hormones, elegant medicinal chemistry and rational design strategies, peptide drugs derived from nature, and major breakthroughs in molecular biology and peptide chemistry that continue to advance the field. We emphasize lessons from earlier approaches that are still relevant today as well as emerging strategies such as integrated venomics and peptide-display libraries that create new avenues for peptide drug discovery. We also discuss the pharmaceutical landscape in which peptide drugs could be particularly valuable and analyse the challenges that need to be addressed for them to reach their full potential.
自近一个世纪前胰岛素问世以来,已有 80 多种肽类药物被推向市场,用于治疗多种疾病,包括糖尿病、癌症、骨质疏松症、多发性硬化症、HIV 感染和慢性疼痛。在本文中,我们总结了肽类药物发现和开发的关键趋势,涵盖了早期专注于人类激素的研究、巧妙的药物化学和合理的设计策略、源自天然的肽类药物以及推动该领域不断发展的分子生物学和肽化学的重大突破。我们强调了今天仍然相关的早期方法的经验教训,以及整合毒液组学和肽展示文库等新兴策略,这些策略为肽类药物的发现开辟了新的途径。我们还讨论了肽类药物可能具有特别价值的药物研发领域,并分析了它们充分发挥潜力所需要解决的挑战。